Cerebrospinal fluid α-synuclein as a potential biomarker for Alzheimer’s disease (P4.174)

JieQiong Li,Jintai Yu,Lan Tan

DOI: https://doi.org/10.1212/wnl.90.15_supplement.p4.174

IF: 9.9

2018-01-01

Neurology

Abstract:Objective: To test whether cerebrospinal fluid (CSF) α-synuclein is altered in Alzheimer’s disease (AD) and different AD pathophysiological profiles based on “ATN” classifications and whether it associated with other AD biomarkers, cognitive decline and imaging evidence of neurodegeneration. Background: More than 50% sporadic AD patients exhibit accumulation of α-synuclein in their brains. CSF α-synuclein could be a potential biomarker of AD. Design/Methods: This prospective case-control study included 385 subjects: 109 cognitively healthy controls, 117 patients with stable mild cognitive impairment (sMCI), 68 patients with progressive mild cognitive impairment (pMCI) and 91 patients with AD dementia from the Alzheimer’s disease Neuroimaging Initiative. The study dates were September 2005, to December 2011. Associations were investigated between CSF α-synuclein and diagnosis, Aβ/tau pathologic features, cognition, brain structure and metabolism. Results: CSF α-synuclein concentration was significantly higher in the AD and pMCI groups compared with the cognitively normal group (P Conclusions: CSF α-synuclein is associated with AD diagnosis and with CSF tau levels, cognition and imaging evidence of neurodegeneration of the disease. This finding implies usefulness for CSF α-synuclein as a potential biomarker for AD. Study Supported by: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI)(National Institutes of Health Grant U01 AG024904) and DOD ADNI(Department of Defense award number W81XWH-12-2-0012). ADNIis funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euro Immun; and F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare;; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research u0026 Development, LLC.; Johnson u0026 Johnson Pharmaceutical Research u0026 Development LLC.; Medpace, Inc.; MerckC Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California Disclosure: Dr. Li has nothing to disclose. Dr. Yu has nothing to disclose. Dr. Tan has nothing to disclose.